Key Events This Week
29 Dec: Sharp gap down and intraday low at Rs.74.11 (-9.74%)
30 Dec - 2 Jan: Stock price remained static at Rs.74.11 despite Sensex gains
2 Jan: Week closes at Rs.74.11, down 9.74% for the week
Mar 05
BSE+NSE Vol: 1.19 k
The next results date for Sarda Proteins Ltd is scheduled for 14 February 2026....
Read full news article
29 Dec: Sharp gap down and intraday low at Rs.74.11 (-9.74%)
30 Dec - 2 Jan: Stock price remained static at Rs.74.11 despite Sensex gains
2 Jan: Week closes at Rs.74.11, down 9.74% for the week

Sarda Proteins Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 December 2025, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trend, and technical outlook.
Read full news article
Sarda Proteins experienced a significant intraday decline, touching a low of Rs 74.11, reflecting a price pressure of 9.74% during today’s trading session. The stock’s performance contrasted sharply with broader market trends, highlighting immediate pressures within the edible oil sector.
Read full news article
Sarda Proteins witnessed a significant gap down at the opening of trading today, with the stock price declining by 9.74% to open at Rs 74.11. This sharp drop reflects heightened market concerns within the edible oil sector, as the stock underperformed both its sector peers and the broader Sensex index.
Read full news article
Sarda Proteins has experienced a revision in its market evaluation, reflecting shifts in its fundamental and technical outlook. This adjustment highlights the evolving challenges faced by the edible oil company, particularly in its financial performance and valuation metrics.
Read full news articleResults for the quarter and nine months ended on 31st Dec 2025
Sarda Proteins Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 inter alia to consider and approve the unaudited financial results for the quarter and nine months ended on 31st December 2025
Intimation of Trading Window Closure
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available